

United Kingdom-Runcorn: Pharmaceutical products
OJ S 215/2016 08/11/2016
Contract award notice
Supplies

Legal Basis:

Directive 2014/24/EU

Section I: Contracting authority

I.1. Name and addresses

Official name: The Secretary of State for Health acting as part of the Crown through the Commercial Medicines Unit (part of the Department of Health)

Postal address: 2nd Floor, Rutland House

Town: Runcorn

NUTS code: UK United Kingdom

Postal code: WA7 2ES

Country: United Kingdom

E-mail: marie.thompson@dh.gsi.gov.uk

Internet address(es):

Main address: <https://cmu.bravosolution.co.uk>

Address of the buyer profile: <https://cmu.bravosolution.co.uk>

I.2. Information about joint procurement

The contract is awarded by a central purchasing body

I.4. Type of the contracting authority

Ministry or any other national or federal authority, including their regional or local subdivisions

I.5. Main activity

Health

Section II: Object

II.1. Scope of the procurement

II.1.1. Title

NHS National Framework Agreement for Generic Pharmaceuticals Wave 10b.

Reference number: CM/PHG/15/5465

II.1.2. Main CPV code

33600000 Pharmaceutical products

II.1.3. Type of contract

Supplies

II.1.4. Short description

NHS Generic Pharmaceuticals Wave 10b

Offer reference number: CM/PHG/15/5465

Period of framework agreement: Dates detailed below with options to extend up to a maximum period of 48 months

Potential periods of call-offs under the framework agreement:

100 % products:

All regions: 1.11.2016 to 28.2.2019 (28 months)

33 % products:

DCE & DSW: 01/11/2016 to 30/06/2018 (20 months)

Housekeeping:

DLS & DNE: 1.11.2016 to 30.6.2017 (8 months);

DLN & DNW: 1.11.2016 to 30.6.2017 (8 months).

The framework agreement is intended for use by the Department of Health, Public Health England and the NHS in England.

The framework may also be used by private sector contractors and agents working on behalf of the above. Please refer to Document 10 in the Invitation To Offer Documents for the list of Purchasing Points.

II.1.6. Information about lots

This contract is divided into lots: yes

II.1.7. Total value of the procurement

Value excluding VAT: 116 000 000,00 GBP

II.2. Description

II.2.1. Title

Wave 10b

Lot No: The tender comprised of the following Lots, DCE,DSW,DLS,DNE,DLN,DNW, for further details of the Lott

II.2.2. Additional CPV code(s)

33690000 Various medicinal products, 33600000 Pharmaceutical products

II.2.3. Place of performance

NUTS code: UK United Kingdom

Main site or place of performance: Please see below.

II.2.4. Description of the procurement

NHS Generic Pharmaceuticals Wave 10b

CM/PHG/15/5465

Period of framework agreement: Dates detailed below with options to extend up to a maximum period of 48 months

Potential periods of call-offs under the framework agreement:

100 % products: All regions: 1.11.2016 to 28.2.2019 (28 months)

33 % products: DCE & DSW: 1.11.2016 to 30.6.2018 (20 months)

Housekeeping:

DLS & DNE: 1.11.2016 to 30.6.2017 (8 months)

DLN & DNW: 1.11.2016 to 30.6.2017 (8 months)

The framework agreement is intended for use by the Department of Health, Public Health England and the NHS in England. The framework may also be used by private sector contractors and agents working on behalf of the above.

Please refer to Document 10 in the Invitation To Offer Documents for the list of Purchasing Points.

II.2.5. Award criteria

Quality criterion - Name: The most economically advantageous tender in terms of the criteria stated in the specifications, in the invitation to tender or to negotiate or in the descriptive document / Weighting: See over

Cost criterion - Name: The most economically advantageous tender in terms of the criteria stated in the specifications, in the invitation to tender or to negotiate or in the descriptive document / Weighting: See over

II.2.11. Information about options

Options: yes

Description of options:

Dates detailed below with options to extend up to a maximum period of 48 months

100 % products: All regions: 1.11.2016 to 28.2.2019 (28 months)

33 % products: DCE & DSW: 1.11.2016 to 30.6.2018 (20 months)

Housekeeping: DLS & DNE: 1.11.2016 to 30.6.2020

DLS & DNE: 1.11.2016 to 30.6.2017 (8 months)

DLN & DNW: 1.11.2016 to 30.6.2017 (8 months)

Please see below for Regions in full.

II.2.13. Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds:
no

II.2.14. Additional information

Lot / Description

DCE — Central

DSW — South Central and South West

DLS — South East and South London

DNE — North East and Yorkshire

DLN — Eastern and North London

DNW — North West.

II.2. Description

II.2.1. Title

Wave 10b

Lot No: All as detailed in Lot 1 and in the Invitation to Offer documents

II.2.2. Additional CPV code(s)

33690000 Various medicinal products, 33600000 Pharmaceutical products

II.2.3. Place of performance

NUTS code: UK United Kingdom

Main site or place of performance: Please see below.

II.2.4. Description of the procurement

NHS Generic Pharmaceuticals Wave 10b

CM/PHG/15/5465

Period of framework agreement: Dates detailed below with options to extend up to a maximum period of 48 months

Potential periods of call-offs under the framework agreement:

100 % products: All regions: 1.11.2016 to 28.2.2019 (28 months)

33 % products: DCE & DSW: 1.11.2016 to 30.6.2018 (20 months)

Housekeeping:

DLS & DNE: 1.11.2016 to 30.6.2017 (8 months)

DLN & DNW: 1.11.2016 to 30.6.2017 (8 months)

The framework agreement is intended for use by the Department of Health, Public Health England and the NHS in England. The framework may also be used by private sector contractors and agents working on behalf of the above.

Please refer to Document 10 in the Invitation To Offer Documents for the list of Purchasing Points.

II.2.5. Award criteria

Quality criterion - Name: The most economically advantageous tender in terms of the criteria stated in the specifications, in the invitation to tender or to negotiate or in the descriptive document / Weighting: See over

Cost criterion - Name: The most economically advantageous tender in terms of the criteria stated in the specifications, in the invitation to tender or to negotiate or in the descriptive document / Weighting: See over

II.2.11. Information about options

Options: yes

Description of options:

Dates detailed below with options to extend up to a maximum period of 48 months

100 % products: All regions: 1.11.2016 to 28.2.2019 (28 months)

33 % products: DCE & DSW: 1.11.2016 to 30.6.2018 (20 months)

Housekeeping:

DLS & DNE: 1.11.2016 to 30.6.2017 (8 months)

DLN & DNW: 1.11.2016 to 30.6.2017 (8 months).

II.2.13. Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds:
no

II.2.14. Additional information

Section IV: Procedure

IV.1. Description

IV.1.1. Type of procedure

Open procedure

IV.1.3. Information about a framework agreement or a dynamic purchasing system

The procurement involves the establishment of a framework agreement

IV.1.8. Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: yes

IV.2. Administrative information

IV.2.1. Previous publication concerning this procedure

Notice number in the OJ S: [2016/S 056-093469](#)

IV.2.8. Information about termination of dynamic purchasing system

IV.2.9. Information about termination of call for competition in the form of a prior information notice

Section V: Award of contract

Contract No: CM/PHG/15/5465

Lot No: 1

Title:

Generic Pharmaceuticals Wave 10b

A contract/lot is awarded: yes

V.2. Award of contract

V.2.1. Date of conclusion of the contract

01/09/2016

V.2.2. Information about tenders

Number of tenders received: 83

Number of tenders received by electronic means: 83

The contract has been awarded to a group of economic operators: no

V.2.3. Name and address of the contractor

Official name: Please see Section VI.3)

National registration number: This Section refers to all Lots within this tender

Town: Please see Section VI.3)

NUTS code: UK United Kingdom

Country: United Kingdom

The contractor is an SME: yes

V.2.4. Information on value of the contract/lot

Total value of the contract/lot: 116 000 000,00 GBP

V.2.5. Information about subcontracting

Section VI: Complementary information

VI.3. Additional information

Awarded Suppliers:

AbbVie

Accord

Actavis

Aguettant

AOP Orphan

AstraZeneca

Aventis Sanofi

Aventis Zentiva

B Braun

Baxter

BGP

Bowmed,

Bristol Laboratories

Casen-Fleet

Chiesi
Consilient Health
Crescent Pharma
Desitin Pharma
Dr Reddy's Laboratories
Drugsrus
Flynn Pharma
Focus Pharmaceuticals
Fresenius Kabi
Generics t-as Mylan
GlaxoSmithKline
Glenmark Generics
Hameln Pharmaceuticals
Hospira
Intrapharm Laboratories
Janssen-Cilag
Kent Pharmaceuticals
LEO Pharma
Logixx Pharma
MaCarthys t-as Martindale
Medac UK
Merck Pharmaceuticals (Serono)
Mercury Pharmaceuticals
Milpharm
Moorfields Eye Hospital NHSFT t-as Moorfields Pharmaceuticals
Napp Pharmaceuticals
Novartis Pharmaceuticals
Panpharma UK
Pfizer
Phoenix Labs
Ranbaxy UK
Roche Products
Rosemont Pharmaceuticals
Sandoz
Seacross UK
Selective Supplies
Stragen UK
Strides Shasun (UK) (Co-pharma)
Syner-Med (PP)
TEVA UK
Torbay PMU
Torrent Pharma (UK)
UCB Pharma
Wockhardt UK
Purchasing points can be provided upon request.

VI.4. Procedures for review

VI.4.1.

Review body

Official name: The Secretary of State for Health acting as part of the Crown through the Commercial Medicines Unit (part of the Department of Health)

Town: Runcorn

Country: United Kingdom

VI.5. Date of dispatch of this notice

03/11/2016